US4057685A
(en)
|
1972-02-02 |
1977-11-08 |
Abbott Laboratories |
Chemically modified endotoxin immunizing agent
|
US4356170A
(en)
|
1981-05-27 |
1982-10-26 |
Canadian Patents & Development Ltd. |
Immunogenic polysaccharide-protein conjugates
|
US4673574A
(en)
|
1981-08-31 |
1987-06-16 |
Anderson Porter W |
Immunogenic conjugates
|
SE8205892D0
(sv)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
|
US4459286A
(en)
|
1983-01-31 |
1984-07-10 |
Merck & Co., Inc. |
Coupled H. influenzae type B vaccine
|
US4663160A
(en)
|
1983-03-14 |
1987-05-05 |
Miles Laboratories, Inc. |
Vaccines for gram-negative bacteria
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4761283A
(en)
|
1983-07-05 |
1988-08-02 |
The University Of Rochester |
Immunogenic conjugates
|
WO1995013796A1
(fr)
|
1993-11-16 |
1995-05-26 |
Depotech Corporation |
Vesicules a taux controle de liberation des principes actifs
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
US4695624A
(en)
|
1984-05-10 |
1987-09-22 |
Merck & Co., Inc. |
Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
|
US4882317A
(en)
|
1984-05-10 |
1989-11-21 |
Merck & Co., Inc. |
Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
|
US4808700A
(en)
|
1984-07-09 |
1989-02-28 |
Praxis Biologics, Inc. |
Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
|
IT1187753B
(it)
|
1985-07-05 |
1987-12-23 |
Sclavo Spa |
Coniugati glicoproteici ad attivita' immunogenica trivalente
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
US4680338A
(en)
|
1985-10-17 |
1987-07-14 |
Immunomedics, Inc. |
Bifunctional linker
|
US5011828A
(en)
|
1985-11-15 |
1991-04-30 |
Michael Goodman |
Immunostimulating guanine derivatives, compositions and methods
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US5206152A
(en)
|
1988-04-08 |
1993-04-27 |
Arch Development Corporation |
Cloning and expression of early growth regulatory protein genes
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
NL8802046A
(nl)
|
1988-08-18 |
1990-03-16 |
Gen Electric |
Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
|
JPH04500203A
(ja)
|
1988-08-25 |
1992-01-16 |
ザ リポソーム カンパニー,インコーポレイテッド |
インフルエンザワクチンおよび新規なアジュバント
|
DE3841091A1
(de)
|
1988-12-07 |
1990-06-13 |
Behringwerke Ag |
Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
EP0378881B1
(fr)
|
1989-01-17 |
1993-06-09 |
ENIRICERCHE S.p.A. |
Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
|
JP2752788B2
(ja)
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
感染および過剰増殖障害の為の組換え療法
|
DK0465529T3
(da)
|
1989-03-21 |
1998-10-05 |
Vical Inc |
Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
JPH0832638B2
(ja)
|
1989-05-25 |
1996-03-29 |
カイロン コーポレイション |
サブミクロン油滴乳剤を含んで成るアジュバント製剤
|
JPH04506662A
(ja)
|
1989-07-14 |
1992-11-19 |
アメリカン・サイアナミド・カンパニー |
接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
|
EP0487587A1
(fr)
|
1989-08-18 |
1992-06-03 |
Chiron Corporation |
Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US4988815A
(en)
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
IT1237764B
(it)
|
1989-11-10 |
1993-06-17 |
Eniricerche Spa |
Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
US5658731A
(en)
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
SE466259B
(sv)
|
1990-05-31 |
1992-01-20 |
Arne Forsgren |
Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
|
US5149655A
(en)
|
1990-06-21 |
1992-09-22 |
Agracetus, Inc. |
Apparatus for genetic transformation
|
GB2276169A
(en)
|
1990-07-05 |
1994-09-21 |
Celltech Ltd |
Antibodies specific for carcinoembryonic antigen
|
ATE128628T1
(de)
|
1990-08-13 |
1995-10-15 |
American Cyanamid Co |
Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
|
NZ239643A
(en)
*
|
1990-09-17 |
1996-05-28 |
North American Vaccine Inc |
Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
|
CA2098849C
(fr)
|
1990-12-20 |
2007-07-10 |
Ralph R. Weichselbaum |
Controle de l'expression de genes par rayonnement ionisant
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
CZ285050B6
(cs)
|
1991-03-01 |
1999-05-12 |
Minnesota Mining And Manufacturing Company |
1-Substituované, 2-substituované-1H-imidazo/4,5-c /chinolin-4-aminy
|
JP3534749B2
(ja)
|
1991-08-20 |
2004-06-07 |
アメリカ合衆国 |
アデノウイルスが介在する胃腸管への遺伝子の輸送
|
US5936076A
(en)
|
1991-08-29 |
1999-08-10 |
Kirin Beer Kabushiki Kaisha |
αgalactosylceramide derivatives
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
WO1993010218A1
(fr)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
IT1262896B
(it)
|
1992-03-06 |
1996-07-22 |
|
Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
IL105325A
(en)
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
JPH07507689A
(ja)
|
1992-06-08 |
1995-08-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
特定組織のターゲティング方法及び組成物
|
EP0644946A4
(fr)
|
1992-06-10 |
1997-03-12 |
Us Health |
Particules vecteurs resistantes a l'inactivation par le serum humain.
|
PT761231E
(pt)
|
1992-06-25 |
2000-06-30 |
Smithkline Beecham Biolog |
Composicao de vacina contendo adjuvantes
|
IL102687A
(en)
|
1992-07-30 |
1997-06-10 |
Yeda Res & Dev |
Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
EP0905253A3
(fr)
|
1992-12-03 |
2000-11-02 |
Genzyme Corporation |
Vecteur adenovira délété de tous les ORF de E4 excepté ORF6
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
EP1175912A1
(fr)
|
1993-03-23 |
2002-01-30 |
SmithKline Beecham Biologics SA |
Compositions vaccinales renfermant le lipide à monophosphorylique 3-O désacétylé
|
US5759573A
(en)
|
1993-04-22 |
1998-06-02 |
Depotech Corporation |
Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
|
ATE304604T1
(de)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
Adenovirus vektoren für gentherapie
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
WO1995002597A1
(fr)
|
1993-07-15 |
1995-01-26 |
Minnesota Mining And Manufacturing Company |
IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
ATE440957T1
(de)
|
1993-09-15 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
Rekombinante alphavirus vektoren
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
DE69434594T2
(de)
|
1993-10-25 |
2006-09-21 |
Canji, Inc., San Diego |
Rekombinante adenoviren-vektor und verfahren zur verwendung
|
WO1995011700A1
(fr)
|
1993-10-29 |
1995-05-04 |
Pharmos Corp. |
Emulsions submicroniques utilisees comme adjuvants de vaccin
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
JP4303315B2
(ja)
|
1994-05-09 |
2009-07-29 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
非交差性レトロウイルスベクター
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
WO1996017072A2
(fr)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Vecteurs d'alphavirus de recombinaison
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
GB9513261D0
(en)
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
ATE424463T1
(de)
|
1996-05-06 |
2009-03-15 |
Oxford Biomedica Ltd |
Rekombinationsunfähige retrovirale vektoren
|
US5770208A
(en)
|
1996-09-11 |
1998-06-23 |
Nabi |
Staphylococcus aureus B-linked hexosamine antigen
|
JP5087758B2
(ja)
|
1997-03-10 |
2012-12-05 |
オタワ ホスピタル リサーチ インスティチュート |
アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US6080725A
(en)
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
GB9712347D0
(en)
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
GB9713156D0
(en)
|
1997-06-20 |
1997-08-27 |
Microbiological Res Authority |
Vaccines
|
AU8586298A
(en)
|
1997-07-25 |
1999-02-16 |
University Of Massachusetts |
Designed protein pores as components for biosensors
|
EP0905243A2
(fr)
*
|
1997-08-05 |
1999-03-31 |
Smithkline Beecham Corporation |
Polynucleotides de Staphylococcus aureus exprimés dans des tissue infectés
|
CA2302554C
(fr)
|
1997-09-05 |
2007-04-10 |
Smithkline Beecham Biologicals S.A. |
Emulsions huile-dans-l'eau contenant des saponines
|
GB9725084D0
(en)
|
1997-11-28 |
1998-01-28 |
Medeva Europ Ltd |
Vaccine compositions
|
CN1200730C
(zh)
|
1998-02-12 |
2005-05-11 |
惠氏控股有限公司 |
用白细胞介素-12配制的肺炎球菌和脑膜炎球菌疫苗
|
US6303114B1
(en)
|
1998-03-05 |
2001-10-16 |
The Medical College Of Ohio |
IL-12 enhancement of immune responses to T-independent antigens
|
BR9909915A
(pt)
|
1998-04-09 |
2000-12-26 |
Smithkline Beecham Biolog |
Composições adjuvantes
|
NZ508013A
(en)
|
1998-05-07 |
2003-08-29 |
Corixa Corp |
Adjuvant composition for use with an antigen in a vaccine composition
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
AU771330B2
(en)
|
1998-08-19 |
2004-03-18 |
Baxter Healthcare Sa |
Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
|
DE69935606T9
(de)
|
1998-10-16 |
2021-03-11 |
Glaxosmithkline Biologicals S.A. |
Adjuvanzsysteme und impfstoffe
|
AU1626199A
(en)
|
1998-12-04 |
2000-06-26 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
A vi-repa conjugate vaccine for immunization against salmonella typhi
|
US20030130212A1
(en)
|
1999-01-14 |
2003-07-10 |
Rossignol Daniel P. |
Administration of an anti-endotoxin drug by intravenous infusion
|
US6551600B2
(en)
|
1999-02-01 |
2003-04-22 |
Eisai Co., Ltd. |
Immunological adjuvant compounds compositions and methods of use thereof
|
ES2228467T3
(es)
|
1999-02-03 |
2005-04-16 |
Biosante Pharmaceuticals, Inc. |
Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso.
|
MY125387A
(en)
|
1999-03-19 |
2006-07-31 |
Smithkline Beecham Biologicals S A |
Vaccine
|
AU781027B2
(en)
|
1999-04-09 |
2005-04-28 |
Department Of Health & Human Services |
Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
WO2001021152A1
(fr)
|
1999-09-24 |
2001-03-29 |
Smithkline Beecham Biologicals S.A. |
Adjuvant comprenant un ether ou ester d'alkyle polyethylene et au moins un tensioactif non ionique
|
CA2383413A1
(fr)
|
1999-09-24 |
2001-03-29 |
Smithkline Beecham Biologicals S.A. |
Vaccins
|
EE200200158A
(et)
|
1999-09-25 |
2003-06-16 |
University Of Iowa Research Foundation |
Immunostimulatoorsed nukleiinhapped
|
CA2396871A1
(fr)
|
2000-01-20 |
2001-12-20 |
Ottawa Health Research Institute |
Acides nucleiques immunostimulateurs permettant d'induire une reponse immunitaire th2
|
GB0007432D0
(en)
|
2000-03-27 |
2000-05-17 |
Microbiological Res Authority |
Proteins for use as carriers in conjugate vaccines
|
ES2334641T3
(es)
|
2000-09-01 |
2010-03-15 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados aza heterociclicos y su uso terapeutico.
|
SG174632A1
(en)
|
2000-09-11 |
2011-10-28 |
Novartis Vaccines & Diagnostic |
Quinolinone derivatives
|
EP1322656B1
(fr)
|
2000-09-26 |
2008-01-16 |
Idera Pharmaceuticals, Inc. |
Modulation de l'activite immunostimulatrice d'analogues oligonucleotidiques immunostimulateurs par des modifications chimiques de position
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
AT410798B
(de)
*
|
2001-01-26 |
2003-07-25 |
Cistem Biotechnologies Gmbh |
Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
|
GB0107661D0
(en)
*
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
US20030035806A1
(en)
|
2001-05-11 |
2003-02-20 |
D'ambra Anello J. |
Novel meningitis conjugate vaccine
|
WO2003020875A2
(fr)
*
|
2001-06-17 |
2003-03-13 |
D-Squared Biotechnologies, Inc. |
Polypeptides immunogenes a surfaces exposees aux staphylocoques
|
JP4516748B2
(ja)
|
2001-09-14 |
2010-08-04 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法
|
JP4360906B2
(ja)
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
|
WO2003035836A2
(fr)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
|
US7321033B2
(en)
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
CN1300165C
(zh)
|
2001-11-27 |
2007-02-14 |
安那迪斯药品股份有限公司 |
3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ES2336094T3
(es)
|
2002-03-29 |
2010-04-08 |
Novartis Vaccines And Diagnostics, Inc. |
Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
|
EP1511746A2
(fr)
|
2002-05-29 |
2005-03-09 |
3M Innovative Properties Company |
Procede permettant d'obtenir des imidazo[4,5-c]pyridin-4-amines
|
JP2005533057A
(ja)
|
2002-06-13 |
2005-11-04 |
ニューヨーク・ユニバーシティ |
合成c−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成c−糖脂質の使用
|
DE60333762D1
(de)
|
2002-08-23 |
2010-09-23 |
Novartis Vaccines & Diagnostic |
Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
|
WO2004060308A2
(fr)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Thiosemicarbazones antiviraux et immunostimulants
|
EP1594524B1
(fr)
|
2003-01-21 |
2012-08-15 |
Novartis Vaccines and Diagnostics, Inc. |
Utilisation de composes de tryptanthrine dans la potentialisation immunologique
|
GB0301554D0
(en)
|
2003-01-23 |
2003-02-26 |
Molecularnature Ltd |
Immunostimulatory compositions
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
CN1980692A
(zh)
|
2003-07-24 |
2007-06-13 |
麦克公司 |
用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
|
RU2337108C2
(ru)
*
|
2003-07-24 |
2008-10-27 |
Мерк Энд Ко., Инк. |
Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
|
RU2236257C1
(ru)
|
2003-09-15 |
2004-09-20 |
Косяков Константин Сергеевич |
Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
|
US7771726B2
(en)
|
2003-10-08 |
2010-08-10 |
New York University |
Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
|
CN1918176A
(zh)
|
2004-02-18 |
2007-02-21 |
默克公司 |
用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
|
US20070172498A1
(en)
|
2004-02-27 |
2007-07-26 |
Anderson Annaliesa S |
Polypeptides for inducing a protective immune response against staphyloococcus aureus
|
CA2560969A1
(fr)
|
2004-03-31 |
2005-11-03 |
New York University |
Nouveaux c-glycolipides synthetiques, leur synthese et utilisation comme adjuvants pour traiter des infections, le cancer et des maladies auto-immunes
|
SI1742659T1
(sl)
|
2004-04-05 |
2013-07-31 |
Zoetis P Llc |
Mikrofluidizirane emulzije olja v vodi in sestavki cepiv
|
JP2008500043A
(ja)
|
2004-05-25 |
2008-01-10 |
メルク エンド カムパニー インコーポレーテッド |
黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド
|
CA2579225A1
(fr)
|
2004-09-17 |
2006-03-30 |
Merck & Co., Inc. |
Polypeptides induisant une reponse immunitaire contre le staphylococcus aureus
|
GB0421079D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CA2583121A1
(fr)
*
|
2004-10-21 |
2007-01-04 |
Wyeth |
Compositions immunogenes a base de polypeptides antigenes de staphylococcus epidermidis
|
EP1843785B1
(fr)
|
2005-01-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Polypeptides pour induire une réponse immune protectrice contre staphylococcus aureus
|
US20060228368A1
(en)
|
2005-04-07 |
2006-10-12 |
Nabi Biopharmaceuticals |
Method of protecting against staphylococcal infection
|
US20060228369A1
(en)
|
2005-04-11 |
2006-10-12 |
Program For Appropriate Technology In Health |
Stabilization and preservation of temperature-sensitive vaccines
|
US7691368B2
(en)
|
2005-04-15 |
2010-04-06 |
Merial Limited |
Vaccine formulations
|
NZ564606A
(en)
|
2005-06-27 |
2010-10-29 |
Glaxosmithkline Biolog Sa |
Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
GB0526038D0
(en)
|
2005-12-21 |
2006-02-01 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
FR2896162B1
(fr)
|
2006-01-13 |
2008-02-15 |
Sanofi Pasteur Sa |
Emulsion huile dans eau thermoreversible
|
EP1998800A2
(fr)
|
2006-01-18 |
2008-12-10 |
University Of Chicago |
Compositions et procédés se rapportant à des protéines de bactéries staphylococciques
|
AR060188A1
(es)
|
2006-03-30 |
2008-05-28 |
Glaxosmithkline Biolog Sa |
Procedimiento de conjugacion
|
JP2009531387A
(ja)
|
2006-03-30 |
2009-09-03 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
WO2007145689A1
(fr)
|
2006-06-12 |
2007-12-21 |
Nabi Biopharmaceuticals |
Utilisation de toxine alpha pour le traitement et la prévention d'infections par le staphylocoque
|
MX2009003325A
(es)
|
2006-10-12 |
2009-04-09 |
Glaxosmithkline Biolog Sa |
Vacuna que comprende un adyuvante de emulsion de aceite en agua.
|
WO2008152447A2
(fr)
|
2006-10-30 |
2008-12-18 |
The University Of Western Ontario |
Anti-infectieux spécifiques de staphylococcus aureus
|
DE102006062398A1
(de)
|
2006-12-20 |
2008-06-26 |
Edi (Experimentelle & Diagnostische Immunologie) Gmbh |
Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
|
GB0700136D0
(en)
*
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
WO2009029132A2
(fr)
|
2007-05-31 |
2009-03-05 |
Merck & Co., Inc. |
PROTÉINES DE LIAISON À L'ANTIGÈNE CIBLANT L'ORF0657n DE S. AUREUS
|
CA2697538C
(fr)
*
|
2007-08-31 |
2019-02-12 |
University Of Chicago |
Procedes et compositions associees pour immuniser contre des maladies et des etats staphylococciques des poumons
|
WO2010039563A2
(fr)
|
2008-09-30 |
2010-04-08 |
University Of Maryland, Baltimore |
Vaccin protecteur contre des biofilms de staphylococcus aureus renfermant des immunogènes associés à la paroi cellulaire
|
EP2208787A1
(fr)
|
2009-01-19 |
2010-07-21 |
Université de Liège |
Polypeptide d'alpha-hémolysine recombinant de Staphylococcus aureus doté d'une suppression dans le domaine de la branche et des insertions de séquences hétérologues
|
BRPI1013780B8
(pt)
*
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|